-
On August 5, 2026, McKesson Corporation reported first-quarter fiscal 2027 results showing sales of US$105.38 billion, higher than a year earlier, while net income and earnings per share from continuing operations declined year-on-year.
-
Alongside these results, McKesson completed a large portion of its long-running share repurchase program and raised adjusted earnings guidance, highlighting management’s confidence in specialty and oncology growth, technology and AI investments, and the company’s ability to return cash to shareholders.
-
Next, we’ll examine how McKesson’s upgraded earnings guidance and specialty growth reshape the existing investment narrative and risk-reward balance.
Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
McKesson Investment Narrative Recap
To own McKesson, you need to believe its scale in drug distribution and growing specialty and oncology exposure can offset pressure on margins and changing healthcare models. The latest quarter reinforces specialty as a key short term catalyst, but the step down in net income and earnings per share keeps regulatory and pricing pressure front of mind as a continuing risk rather than a new one.
The most relevant recent announcement alongside earnings is the near completion of McKesson’s multi year US$29,000 million buyback authorization, with US$23,475.49 million already deployed. Combined with higher adjusted earnings guidance and a 15% dividend increase to US$0.94 per share, this capital return profile sits squarely against the core catalyst of specialty and oncology growth, while still leaving investors exposed to the evolving drug pricing backdrop.
Yet behind the upgraded guidance and large buybacks, investors should be aware of how sustained policy pressure on drug pricing could…
McKesson’s narrative projects $502.2 billion revenue and $6.3 billion earnings by 2029.
Uncover how McKesson’s forecasts yield a $980.80 fair value, a 13% upside to its current price.
Exploring Other Perspectives
Four members of the Simply Wall St Community currently see McKesson’s fair value between US$827.49 and US$1,667.78, reflecting very different expectations. Set against that, the recent guidance raise tied to specialty and oncology strength gives you a concrete catalyst to compare with these varied views.
Explore 4 other fair value estimates on McKesson – why the stock might be worth as much as 92% more than the current price!
